Genzyme Responds to Sanofi-Aventis Letter
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) has responded to a letter sent earlier by Sanofi-Aventis relating to its unsolicited tender offer. Genzyme's response reiterates the unanimous view of its board of directors that the $69-per-share offer price is not an appropriate starting point for discussions because it dramatically undervalues the company.
Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has sent a letter to Genzyme Corporation (NASDAQ: GENZ) requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme's Schedule 14D-9.
Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year
- Details
- Category: Abbott
Abbott (NYSE: ABT) was once again included on both the Dow Jones Sustainability World Index and North America Index, following the reassessment of 2010 scores announced by Dow Jones Indexes and SAM. This is the sixth consecutive year that Abbott has been named to both Dow Jones Sustainability Indexes (DJSI).
Bayer raises its brand profile
- Details
- Category: Bayer
The Bayer Group plans to greatly strengthen the "Bayer" umbrella brand and steadily reduce the number of its other corporate brands.
KOMBIGLYZE™ XR tablets approved in the US
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) approved KOMBIGLYZE™ XR for the treatment of type 2 diabetes in adults.
Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
- Details
- Category: Amgen
Amgen Inc. (Nasdaq: AMGN), Pfizer Inc. (NYSE: PFE) and world-class professional golfer Phil Mickelson, have entered into a partnership to share Phil's experience with his diagnosis of psoriatic arthritis and treatment with Enbrel(R) (etanercept), and to encourage patients with similar symptoms to visit their doctor for proper assessment and care.
Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) is pleased to announce that it has won the Best New Drug awardfor Prolia(TM) (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the2010 Scrip Awards ceremony Nov. 4 in London.
More Pharma News ...
- New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate
- Sanofi Pasteur's Dengue Vaccine in Final Stage of Clinical Development
- Lilly CEO Calls for a 'Wave of Invention' to Reduce the Toll of Diabetes
- Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion
- Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Early-Stage Oncology Compound
- Lundbeck expects to deliver solid profits during a period of new product launches and patent expiries
- Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin